Last updated: July 6, 2020
Sponsor: Ruijin Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoma, B-cell
Lymphoma
Treatment
N/AClinical Study ID
NCT04435743
LEN-NHL
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosed as B-cell non-Hodgkin's lymphoma
Voluntary participation in this study and the signing of an informed consent form
The researchers assessed that the patient will benefit from the treatment oflenalidomide single drug or lenalidomide combined with rituximab (with or withoutother drugs)
Exclusion
Exclusion Criteria:
Contradictions to any drug in the treatment regimen
Pregnant or lactating women
Patients who were not considered suitable for the study by the researchers
Study Design
Total Participants: 1000
Study Start date:
November 01, 2019
Estimated Completion Date:
December 31, 2022
Study Description
Connect with a study center
Shanghai Ruijin Hospital
Shanghai,
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.